| Budget Amount *help |
¥45,110,000 (Direct Cost: ¥34,700,000、Indirect Cost: ¥10,410,000)
Fiscal Year 2014: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2013: ¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2012: ¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
|
|---|
| Outline of Final Research Achievements |
Influenza A virus (IAV) causes significant morbidity and mortality. We have studied the viral pathogenicity and the host cellular factors involved in the pathogenicity of multiorgan failure (MOF). We proposed a new concept on the pathogenicity of MOF, the“influenza virus-cytokine-trypsin”cycle interconnected with the“metabolic disorders-cytokine". These cycles provide new treatment concepts for ATP crisis and MOF. One is diisopropylamine dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase 4 for glucose metabolism and the other is bezafibrate which up-regulates long-chain fatty acid metabolism. We also identified that IAV infection induces GSK-3β-mediated β-catenin degradation in the adherens junctional complexes and induces vascular hyperpermeability. Furthermore, we established SmartAmp system for detection of thermolabile carnitine palmitoyltransferase 2 SNPs as risk factors for influenza associated encephalopathy in the infected young children.
|
